N-Phenylisopropyl-N-(γ-phenylpropyl)amin | 13005-65-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Phenylisopropyl-N-(γ-phenylpropyl)amin
• 英文别名: alpha-Methyl-N-(3-phenylpropyl)phenethylamine；1-phenyl-N-(3-phenylpropyl)propan-2-amine
• CAS: 13005-65-7
• 化学式: C₁₈H₂₃N
• 分子量: 253.387
• InChiKey: CYWPIEBWQAZHQX-UHFFFAOYSA-N

物化性质

• 沸点：
  381.3±21.0 °C(Predicted)
• 密度：
  0.981±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  苯基丙酮 、 3-苯基-1-丙胺 在 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 生成 N-Phenylisopropyl-N-(γ-phenylpropyl)amin
  参考文献：
  名称：

  工程亚胺还原酶催化对映异构体合成烷基化安非他明

  摘要：

  较少空间酮对 M5 表现出较低的立体选择性，因为它们难以限制亚胺中间体的自由旋转。从M5获得了具有催化活性的工程化对映互补亚胺还原酶。我们确定了在控制立体选择性中发挥重要作用的四个关键残基。获得了两个突变体，I149Y-W234L（高达99％ S ee ）和L200M-F260M（高达99％ R ee ），对测试的底物表现出优异的立体选择性，为合成烷基化安非他明提供了有价值的生物催化剂。

  DOI：

  10.1021/acs.orglett.4c02600

文献信息

• [EN] NOVEL CYP34A-SPECIFIC INHIBITORS AND METHODS OF USING SAME<br/>[FR] NOUVEAUX INHIBITEURS SPÉCIFIQUES DU CYTOCHROME CYP3A4 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2017044742A1

  公开（公告）日：2017-03-16

  The present invention includes novel compositions inhibiting CYP3 A4. The present invention further includes a novel method of inhibiting CYP3A4 in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the subject is further administered at least one additional therapeutic agent.

  本发明包括抑制CYP3A4的新型组合物。本发明还包括一种在需要的受试者中抑制CYP3A4的新方法，该方法包括向受试者施用本发明中化合物的有效量。在一个实施例中，受试者还会被施用至少一种额外的治疗药物。
• Dimethylamine as a Substrate in Hydroaminoalkylation Reactions
  作者：Jens Bielefeld、Sven Doye

  DOI：10.1002/anie.201708959

  日期：2017.11.20

  Size matters: For the first time since catalytic hydroaminoalkylation chemistry started 37 years ago, dimethylamine can efficiently be added to alkenes using an inexpensive and easily obtainable Ti catalyst. The size of the flask determines whether the reaction gives monohydroaminoalkylation or dihydroaminoalkylation.

  尺寸问题：自37年前开始进行催化加氢氨基烷基化化学反应以来，使用廉价且易于获得的Ti催化剂可将二甲胺有效地添加到烯烃中。烧瓶的大小决定了反应是进行单氢氨基烷基化反应还是二氢氨基烷基化反应。
• Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse
  申请人：University of Kentucky Research Foundation

  公开号：US20170304227A1

  公开（公告）日：2017-10-26

  The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

  本发明涉及治疗中枢神经系统疾病或病理、进食障碍、物质使用障碍、药物依赖/滥用及其戒断的方法，包括给予至少一种N-苯基烷基苯丙胺衍生物和包含至少一种N-苯基烷基苯丙胺衍生物的药物组合物给需要的个体。
• Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
  申请人：University of Kentucky Research Foundation

  公开号：US10668030B2

  公开（公告）日：2020-06-02

  The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

  本发明涉及治疗中枢神经系统疾病或病理、饮食失调或药物使用失调、药物依赖/滥用及其戒断的方法，包括向有需要的个体施用至少一种N-苯基烷基苯丙胺衍生物和包含至少一种N-苯基烷基苯丙胺衍生物的药物组合物。
• VESICULAR MONOAMINE TRANSPORTER-2 LIGANDS AND THEIR USE IN THE TREATMENT OF PSYCHOSTIMULANT ABUSE
  申请人：University of Kentucky Research Foundation

  公开号：US20200237688A1

  公开（公告）日：2020-07-30

  The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.